Table 1.
General Description | Median (range) n | % |
---|---|---|
Age, y | 56 (18–73) | |
No. of patients | 98 | |
Female sex | 60 | 61 |
Double lung recipientsa | 67 | 68 |
CMV serology positive pre-LTx | 84 | 86 |
CMV mismatchb | 9 | 9 |
EBV serology positive pre-LTx | 95 | 97 |
EBV mismatch | 9 | 9 |
Dominant CNI | ||
Cyclosporine | 79 | 80 |
Tacrolimus | 19 | 20 |
Underlying disease | ||
Pulmonary fibrosis | 30 | 31 |
COPD | 32 | 33 |
Alfa-1 antitrypsin deficiency | 10 | 10 |
Cystic fibrosis | 6 | 6 |
Retransplantation | 6 | 6 |
Pulmonary artery hypertension | 4 | 4 |
RA bronchiolitis | 2 | 2 |
Sarcoidosis | 2 | 2 |
Sclerodermia | 2 | 2 |
Bronchiectasies | 2 | 2 |
Alveolitis | 1 | 1 |
Lymphangioleiomyomatosis | 1 | 1 |
Abbreviations: CMV, human cytomegalovirus; CNI, calcineurin inhibitor; COPD, chronic obstructive pulmonary disease; EBV, Epstein-Barr virus; LTx, lung transplantation; RA bronchiolitis, rheumatoid arthritis bronchiolitis.
aAll other received single lung transplantations.
bDonor being positive for antibodies against CMV/EBV and recipient being negative prior to transplantation.